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Background: Juvenile X-linked retinoschisis (RS1, OMIM: 312700) is a hereditary vitreoretinal 
dystrophy characterized by bilateral foveal schisis and, in half of the patients, splitting through 
the nerve fiber layer in the peripheral retina. In the first decade of life, patients usually develop 
a decrease in visual acuity. Long-term visual outcomes can be poor due to the limited number 
of known successful treatments.
Purpose: The purposes of this study were to present, for the first time, a p.Arg197Cys 
missense mutation in the RS1 gene (OMIM: 300839) in a four-generation Italian family with 
RS1 and to examine the clinical response to the treatment with acetazolamide tablets alone or 
in combination with dorzolamide eye drops as assessed by spectral-domain optical coherence 
tomography (SD-OCT).
Methods: Eleven individuals, including two brothers with RS1 (patients 1 and 2), underwent 
a full medical history and a comprehensive ocular examination that involved SD-OCT, fluo-
rescein angiography, electroretinography and DNA analysis. Each RS1 patient received oral 
acetazolamide (375 mg daily) during the first three months. Thereafter, patient 1 continued 
only with dorzolamide eyedrops three times a day for a period of three months, while patient 2 
spontaneously stopped both medications.
Results: Sequence analysis of the RS1 gene identified a hemizygous c.589C.T (p.Arg197Cys) 
missense mutation in exon 6, which has not been previously reported in an Italian family. 
A different response to the medical therapy was observed in the four eyes of the two affected 
brothers hemizygous for this abnormality. Of note, after acetazolamide interruption, a rebound 
effect on cystoid macular edema reduced the beneficial effects of the initial therapy for RS1 
from p.Arg197Cys mutation. Indeed, a minimal rebound effect on cystoid macular edema, and 
an improvement in visual acuity, was observed in patient 1 during the six months of treatment. 
Conversely, in patient 2, an initial improvement in cystoid macular edema was not associated 
with visual acuity changes, followed by a marked rebound effect.
Conclusion: This study showed that the sequential use of acetazolamide tablets and dorzolamide 
eye drops should be considered and studied further as a possible treatment for macular edema 
and visual impairment in patients with RS1 from a hemizygous p.Arg197Cys mutation.
Keywords: juvenile X-linked retinoschisis, oral acetazolamide, topical dorzolamide, cystoid 
macular edema, macular schisis, foveal zone thickness
Introduction
Juvenile X-linked retinoschisis (RS1) is a hereditary vitreoretinal disorder that shows 
radiating cystoid changes in the macula with or without peripheral retinoschisis, 
early onset of visual loss, abnormal electroretinograms (ERGs) and, in some cases, 
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vitreous hemorrhage and/or retinal detachment. RS1 affects 
predominantly male subjects. It is transmitted as an X-linked 
recessive trait and female carriers are usually asymptomatic. 
The penetrance of RS1 is almost complete but clinical 
expression is highly variable.1 As previously reported, the 
prevalence of RS1 is between 1:5,000 and 1:25,000.2,3 Visual 
impairment is usually mild until the fourth decade of life; 
thereafter, progressive visual deterioration often occurs.
The RS1 gene (OMIM: 300839) maps to Xp22.13, has six 
exons and encodes retinoschisin, a secreted 224 amino acid 
protein associated with the disease, abundantly expressed 
in both cone and rod photoreceptors and bipolar cells of the 
retina and the pineal gland.
The gene contains a highly conserved region in exons 4–6 
known as the discoidin domain, shared with a number of other 
proteins.4 The discoidin domain is implicated in cell–cell 
adhesion and phospholipid binding.5 Cell expression studies 
showed that disease-associated missense mutations result in 
aberrant protein synthesis and retention in the endoplasmic 
reticulum, producing non-functional products.
The ERGs of the most affected males demonstrate nor-
mal or near-normal a-waves, characteristic of photoreceptor 
function, but often substantially reduced b-waves, originating 
from inner retinal cell activity.6 For several decades, the ERG 
has been the major diagnostic technique for RS1.
Relatively recently, optical coherence tomography (OCT) 
has changed the diagnostic approach for various ocular dis-
eases in both anterior and posterior segments,7–12 including 
RS1. Indeed, at present spectral domain OCT (SD-OCT) is 
the most useful diagnostic tool for this disease. Even in a non-
cooperative child, a single OCT B-scan of the foveal area is 
sufficient to detect RS1 signs and to make a differential diag-
nosis with other diseases causing visual loss in young boys.
Long-term visual outcomes can be poor due to the limited 
number of known successful treatments. A beneficial effect 
from the use of a topic or, alternatively, systemic carbonic 
anhydrase inhibitor (CAI) has been reported in patients with 
cystoid macular edema in retinal dystrophies including RS1. 
One study described the successful treatment of a patient with 
a p.Arg197Cys, and other mutations, in RS1.13 No follow-up 
was reported in this study after the discontinuation of the 
therapy with acetazolamide. Further studies on CAI treatment 
showed a rebound effect in RS1 in a small subset of patients 
only.14 A different response to treatment with oral CAI might 
be possible for various genotypes in RS1 (including the side 
effects), as previously reported.15–18
The purposes of this study were, therefore, to report for 
the first time a p.Arg197Cys missense mutation in the RS1 
gene in an Italian family with RS1 and to explore the clinical 
response, as assessed by SD-OCT, in two affected brothers 
hemizygous for this mutation, to the treatment with oral 
acetazolamide alone or in combination with dorzolamide 
eye drops.
Materials and methods
subjects and study procedure
This study was conducted at the Eye Clinic of the Depart-
ment of Surgical Sciences, University of Cagliari, Italy. The 
study adhered to the tenets of the Declaration of Helsinki and 
was approved by the Office of Research Ethics, University 
of Cagliari. All subjects signed informed consents prior to 
their participation in the study.
Individuals from a four-generation family with RS1 were 
recruited at Budduso, a village in Olbia Province, Italy. The 
family consisted of 20 members with four affected subjects 
(Figure 1). Eleven individuals, including two brothers with 
RS1, 18 and 20 years old (patients 1 and 2, respectively), 
underwent a full medical history and a comprehensive ocular 
examination, which involved best-corrected visual acuity, 
slit lamp examinations, fundus examination in mydriasis, 
SD-OCT scans, fluorescein angiography, electrophysiology 
and genetic analysis.
Patients were diagnosed as having RS1 based on the 
clinical findings, which included a decrease in visual acuity 
(VA), stellate-shaped cavities in the macular region on the 
retinal exam, and a decrease in the b-wave amplitude on ERG 
examination. The diagnosis was confirmed by molecular 
genetic analysis of RS1 gene, which revealed a p.Arg197Cys 
missense mutation (Figure 1).
genetic investigation
Peripheral blood samples with EDTA anticoagulant were 
collected from each participant of the study. Genomic DNA 
was extracted using GeneCatcher™ gDNA Automated Blood 
Kit. All six exons and the flanking intronic regions of the 
RS1 gene were amplified by polymerase chain reaction with 
oligonucleotide primers published.4 The PCR products were 
analyzed on 2% agarose gel stained with ethidium bromide 
and purified with a DNA extraction kit (QIA-quick Gel 
Extraction Kit; Qiagen, Hilden, Germany). PCR products 
from all exons were directly sequenced with the Bigdyes 
termination method.
Clinical assessment
Both patients with RS1 from p.Arg197Cys mutation (patients 
1 and 2) were orally treated with 375 mg  acetazolamide 
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tablets once daily simultaneously and the treatment was 
maintained for three months (Diamox; Teofarma s.r.l., Via 
F.lli Cervi, 8 27010 Valle Salimbene, PV, Italy). At the end 
of the 3rd month, patient 1 continued therapy only with 2% 
dorzolamide collyrium (Trusopt; Santen Switzerland SA, 
Geneva, Switzerland) three times daily in both eyes, while 
the older brother (patient 2) refused any further treatment.
The response to the treatment was monitored by mea-
suring VA and by performing SD-OCT (Cirrus HD-OCT 
4000; Carl Zeiss Meditec, Inc., Dublin, CA, USA) using 
the macular cube 512×128 and HD 5 line raster scanning 
protocol, at baseline, at the end of the 3rd and 6th months. 
Changes in the foveal zone thickness (FZT), as detected in 
the central subfield of the macular thickness map (ie, in the 
central 1,000 µm of the foveal region in the ETDRS grid, 
from ILM to RPE), were calculated from the start to the end 
of the medical treatment. As previously reported, more than 
19.6% reduction in FZT was considered to be substantial, 
as well as a change in logMAR score of 0.12 (based on 
previously reported normal variability between visits in 
non-treated eyes).19
Results
Sequence analysis of the RS1 gene identified a hemizygous 
c.589C.T (p.Arg197Cys) missense mutation in exon 6. 
The patient’s mother was heterozygous c.589C.T and also 
the patient’s unaffected sister was heterozygous for this 
mutation. The nucleotide change in the patients predicted an 
amino acid change from arginine (CGC) to cysteine (TGC). 
This mutation was previously reported in a British patient 
but not in patients with Italian ethnicity.13
Fluorescein angiography showed that macular schisis 
cavities were not associated with late leakage. ERG examina-
tion showed that both patients had a significantly reduced rod 
response and decreased cone responses for the amplitudes 
of a-waves and b-waves.
A different response to the medical therapy was observed 
in the four eyes of the two brothers on examination by 
SD-OCT. Relative changes were calculated with respect to 
baseline values (Tables 1 and 2).
Patient 1 underwent complete therapy. At the start of treat-
ment, the FZT was 563 µm in the right eye (RE) and 501 µm 
in the left eye (LE), and VA was 3/10 (logMAR 0.522) in both 
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Figure 1 Family pedigree of an italian family with juvenile X-linked retinoschisis from a p.arg197Cys mutation (village of Budduso, sardinia).
Notes: *individuals genotyped for RS1. Unaffected individuals are represented by empty symbols. Solid squares denote affected males. Female carriers, when identified, are 
indicated by a shade dot inside a circle. Individuals crossed by a line represents already passed away. Each generation is identified by a Roman numeral and each individual 
within the same generation is numbered consecutively by an arabic numeral. The patients are indicated by an arrow.
Table 1 Changes in foveal zone thickness
Baseline Three months Six months
Patient 1
right eye (µm) 563 430 440
left eye (µm) 501 371 277
Patient 2
right eye (µm) 496 377 509
left eye (µm) 519 455 501
Notes: Patient 1: Underwent complete therapy (sequential treatment with aceta-
zolamide tablet and dorzolamide eye drops). Patient 2: spontaneously interrupted 
any therapy after oral acetazolamide.
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eyes (OU) on the Snellen chart. After the first three months 
of acetazolamide treatment (Figure 2), the FZT was 430 µm 
in the RE (-23.62%) and 371 µm in the LE (-25.94%), and 
VA had improved to 6/10 in the RE (logMAR 0.221) and 
5/10 in the LE (logMAR 0.301). At the end of the 6th month, 
after treatment with 2% dorzolamide three times a day for 
three months, the FZT was 440 µm in the RE (-21.84%) 
and 277 µm in the LE (-44.71%), and VA remained 6/10 
in the RE (logMAR 0.221) and 5/10 in the LE (logMAR 
0.301) (Table 1).
In patient 2, the FZT was 496 µm in the RE and 519 µm 
in the LE, and VA was 4/10 (logMAR 0.397) in the RE and 
5/10 (logMAR 0.301) in the LE before treatment. After aceta-
zolamide treatment, the FZT was 377 µm in RE (-23.99%) 
and 455 µm in the LE (-12.33%), but VA was unchanged 
in OU. At the end of the 6th month, the FZT was 509 µm in 
the RE (+2.62%) and 501 µm in the LE (-3.46%), and VA 
was unchanged in OU (Table 2).
Discussion
RS1 is caused by mutations of the RS1 gene that encodes 
for retinoschisin. Retinoschisin promotes cell adhesion and 
its dysfunction leads to the formation of cystoid cavities in 
the inner nuclear and outer plexiform layers of the retina.20 
Clinical effects of CAI are presumed to be attributed to their 
facilitation effect on the fluid transport across the retinal 
pigment epithelium, decreasing the volume of the subretinal 
space and increasing retinal adhesiveness.21 Apushkin and 
Fishman19 in their study demonstrated a reduction in the 
foveal thickness in seven of the eight patients affected by 
RS1, who were treated with 2% dorzolamide eye drops, and 
a concomitant improvement in the VA in five patients.19 In 
a further small case study, it was found that the response to 
dorzolamide eye drops was independent of the type of the 
underlying mutation.20
To date, 196 different mutations in the RS1 gene are 
known to cause RS1 (Leiden Open Variation Database, 
LOVD, version 2.0, Build 35; http://grenada.lumc.nl/
LOVD2/eye/home.php?select_db=RS1). More than 80% 
are nucleotide substitutions, with missense mutations being 
the predominant type, mostly found in exons 4–6 encoding 
the discoidin domain. However, the functional impact of 
most missense variants is not well known. In general, a lack 
of relationship between the response to dorzolamide and 
the type of mutation in RS1 gene has been observed by dif-
ferent authors.13,20 In particular, structure-based analysis of 
Table 2 Changes in visual acuity
Baseline 3 months 6 months
Patient 1
right eye 3/10 (logMar 0.522) 6/10 (logMar 0.221) 6/10 (logMar 0.221)
left eye 3/10 (logMar 0.522) 5/10 (logMar 0.301) 5/10 (logMar 0.301)
Patient 2
right eye 4/10 (logMar 0.397) 4/10 (logMar 0.397) 4/10 (logMar 0.397)
left eye 5/10 (logMar 0.301) 5/10 (logMar 0.301) 5/10 (logMar 0.301)
Notes: Patient 1: Underwent complete therapy (sequential treatment with acetazolamide tablet and dorzolamide eye drops). Patient 2: spontaneously interrupted any 
therapy after oral acetazolamide.
Figure 2 Spectral-domain optical coherence tomography (SD-OCT) imaging in patient 1 with juvenile X-linked retinoschisis from p.Arg197Cys mutation during the first 
3 months of therapy with oral acetazolamide (Cirrus hD-OCT 4000; Carl Zeiss Meditec, inc., Dublin, Ca, Usa). (A) Baseline (pretreatment) OCT scan: visual acuity 
was 3/10 and foveal zone thickness 563 µm. (B) At the end of the 3rd month, OCT scan showed a significant improvement in visual acuity (6/10) and in foveal zone 
thickness (430 µm).
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p.Arg197Cys mutation predicts a mild change in retinoschisin 
protein, which should not affect the protein fold.22
A case report on the use of oral acetazolamide in an 
8-year-old child diagnosed with RS1 demonstrated a near 
complete resolution of macular edema, with an increased 
VA even when the macular edema recurred on cessation of 
treatment.14
Long-term treatment of oral acetazolamide may be con-
traindicated in some patients because of potential systemic 
side effects, such as electrolyte imbalance, weakness, renal 
dysfunction, depression, metabolic acidosis, and mental 
lethargy. Because of these reasons, a topical medication 
would be preferable for therapy over a prolonged period 
of time. Clearly, topical dorzolamide may also lead to side 
effects, which are prevalently local, such as burning sensation 
of eyes, eye pruritus/discomfort, and local ocular hypersen-
sitivity reaction.
Our study showed that oral treatment of acetazolamide 
for 3 months substantially reduced macular thickness in both 
patients and increased VA in one (patient 1), without any sys-
temic adverse drug effects. The data of our study also showed 
that after the cessation of acetazolamide treatment, a rebound 
effect on cystoid macular edema may reduce the beneficial 
effects of initial therapy for RS1 from p.Arg197Cys mutation. 
This aspect highlights the difficulties in properly choosing 
how to continue the treatment strategy after the cessation of 
oral acetazolamide.
Of note, in patient 1 (who underwent subsequent treat-
ment with dorzolamide eyedrops) the appearance of macular 
thickening was limited by sustained therapy with topical 
CAI, avoiding the return to the pretreatment levels (baseline 
values). In fact, the sequential use of topical 2% dorzolamide 
resulted only in a slight increase in FZT without any changes 
in VA. Overall, during the 6 months of therapy, sequential 
administration of CAI, orally and topically, induced a signifi-
cant improvement in both cystoid macular edema and VA, 
without any systemic adverse drug effects.
Conversely, in patient 2, the initial improvement in cystoid 
macular edema was not associated with VA changes (dur-
ing therapy with oral acetazolamide), followed by a marked 
rebound effect after cessation of the therapy. Whether the 
absence of an effect on VA predicts the rebound effect is 
speculative since nonresponders in VA to CAI treatment 
have been reported previously.16,17,23
Conclusion
In conclusion, the results of this study suggest that cessa-
tion of oral acetazolamide may result in a rebound effect on 
cystoid macular edema in patients with RS1 from a specific 
gene mutation in the RS1 (c.589C.T, p.Arg197Cys), as well 
as that the combined use of oral and topical CAI should be 
considered and studied further for a possible treatment of 
maculopathy and visual impairment in affected subjects 
with this abnormality. In this sense, CAI withdrawal should 
be gradual, and the dilution of the medication with eyedrops 
may be desirable. Consequently, until long-term efficacy and 
safety of a proper treatment protocol for XLRS maculopathy 
is established, we recommend caution in suddenly interrupt-
ing the therapeutic regimen with CAI.
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